About Electrogenic aspartate/glutamate antiporter SLC25A12, mitochondrial
Electrogenic aspartate/glutamate antiporter SLC25A12, mitochondrial (SLC25A12) is a protein
from Homo sapiens identified by UniProt accession
O75746, 678 residues long.
MolForge cross-references it against 0 known binders and
98 disease associations.
Target properties
| Protein name | Electrogenic aspartate/glutamate antiporter SLC25A12, mitochondrial |
|---|
| UniProt accession | O75746 |
|---|
| Gene | SLC25A12 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 678 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (98)
Diseases linked to this target (Open Targets).
- Epileptic encephalopathy with global cerebral demyelination · score 0.77
- developmental and epileptic encephalopathy, 39 · score 0.76
- genetic disorder · score 0.41
- Global developmental delay · score 0.37
- Abnormality of refraction · score 0.30
- developmental and epileptic encephalopathy · score 0.27
- developmental and epileptic encephalopathy, 1 · score 0.27
- infantile epileptic-dyskinetic encephalopathy · score 0.27
- West syndrome · score 0.27
- Spasticity - intellectual disability - X-linked epilepsy · score 0.27
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O75746-F1 | alphafold | PREDICTED | 82.84 | — |
Amino-acid sequence (678 residues)
MAVKVQTTKR GDPHELRNIF LQYASTEVDG ERYMTPEDFV QRYLGLYNDP NSNPKIVQLL AGVADQTKDG LISYQEFLAF ESVLCAPDSM FIVAFQLFDK SGNGEVTFEN VKEIFGQTII HHHIPFNWDC EFIRLHFGHN RKKHLNYTEF TQFLQELQLE HARQAFALKD KSKSGMISGL DFSDIMVTIR SHMLTPFVEE NLVSAAGGSI SHQVSFSYFN AFNSLLNNME LVRKIYSTLA GTRKDVEVTK EEFAQSAIRY GQVTPLEIDI LYQLADLYNA SGRLTLADIE RIAPLAEGAL PYNLAELQRQ QSPGLGRPIW LQIAESAYRF TLGSVAGAVG ATAVYPIDLV KTRMQNQRGS GSVVGELMYK NSFDCFKKVL RYEGFFGLYR GLIPQLIGVA PEKAIKLTVN DFVRDKFTRR DGSVPLPAEV LAGGCAGGSQ VIFTNPLEIV KIRLQVAGEI TTGPRVSALN VLRDLGIFGL YKGAKACFLR DIPFSAIYFP VYAHCKLLLA DENGHVGGLN LLAAGAMAGV PAASLVTPAD VIKTRLQVAA RAGQTTYSGV IDCFRKILRE EGPSAFWKGT AARVFRSSPQ FGVTLVTYEL LQRWFYIDFG GLKPAGSEPT PKSRIADLPP ANPDHIGGYR LATATFAGIE NKFGLYLPKF KSPSVAVVQP KAAVAATQ
Explore Electrogenic aspartate/glutamate antiporter SLC25A12, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets